Mylan wins FDA approval for generic Parkinson's drug

Oct 05, 2009 (Datamonitor via COMTEX) Mylan has announced that its subsidiary Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application, or ANDA, for Carbidopa and Levodopa tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250mg.
Carbidopa and Levodopa tablets are the generic version of Bristol Myers Squibb's Parkinson's treatment Sinemet, 10mg/100mg, 25mg/100mg and 25mg/250mg. Mylan has launched this product.
Mylan and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.